Close Menu
The Business TimesThe Business Times
  • Home
  • News
  • Business
  • Finance
  • Economy
  • Markets
  • Investing
  • Real Estate
  • Crypto
  • Fintech
  • Forex
  • More
    • Politics
    • Web Stories
    • Spotlight
    • Press Release
What's On

Upstart’s Breakout May Occur Sooner Than Expected – H2 2026 Macro Risks (NASDAQ:UPST)

1 September 2026

Ametek: The Quiet Control Layer Behind The Next Industrial Investment Cycle (NYSE:AME)

1 September 2026

Top 25 Dividend Stock Opportunities For September 2026

1 September 2026

Cango Inc. (CANG) Q2 2026 Earnings Call Transcript

1 September 2026

Betmakers Technology Group Ltd (TPBTF) Q4 2026 Earnings Call Transcript

1 September 2026
Facebook X (Twitter) Instagram
Business Tuesday, Sep 1
The Business TimesThe Business Times
Newsletter
  • Home
  • News
  • Business
  • Finance
  • Economy
  • Markets
  • Investing
  • Real Estate
  • Crypto
  • Fintech
  • Forex
  • More
    • Politics
    • Web Stories
    • Spotlight
    • Press Release
The Business TimesThe Business Times
Home » Medartis Holding AG (MDRSF) Discusses Strategy Roadmap and Innovation in Upper Extremities and Hand Products Transcript
News

Medartis Holding AG (MDRSF) Discusses Strategy Roadmap and Innovation in Upper Extremities and Hand Products Transcript

thebusinesstimes.co.ukBy thebusinesstimes.co.uk5 June 20261 Views
Facebook Twitter LinkedIn Reddit Telegram WhatsApp Pinterest Tumblr VKontakte Email
Medartis Holding AG (MDRSF) Discusses Strategy Roadmap and Innovation in Upper Extremities and Hand Products Transcript
Share
Facebook Twitter LinkedIn Pinterest Email

Medartis Holding AG (MDRSF) Discusses Strategy Roadmap and Innovation in Upper Extremities and Hand Products June 4, 2026 3:00 AM EDT

Company Participants

Matthias Schupp – CEO & Member of the Executive Management Board
Marc Ammann – Executive Vice President of R&D and Innovation and Member of the Executive Management Board
Daniel Herren
Fabian Hildbrand
Peter Hackel – CFO & Member of Executive Management Board
Mario Della Cassa

Conference Call Participants

Sandra Dietschy – Octavian AG, Research Division
Daniel Jelovcan – Zürcher Kantonalbank, Research Division
Edward Hall – Stifel, Nicolaus & Company, Incorporated, Research Division

Presentation

Matthias Schupp
CEO & Member of the Executive Management Board

Okay. So, good morning, everybody. Maybe we can take a seat. You can put down a little bit of volume. We are not so many people. Yes. Again, welcome to now, rainy Basel. The sun from yesterday is gone. But I’m very happy that you made it to our investor and media event around the FESSH, the world’s biggest hand congress. And I’m so surprised to look what Fabian — I love it when Fabian has also here our products on the table. And by the way, the sexy nail is here. Some people who discussed yesterday night with me, they know about the sexy nail. It’s our brand-new launch for the U.S. some are looking at what we are doing. Is this becoming an erotic shop? No. Medartis is just becoming disruptive, different. And I hope you see this also throughout the FESSH. We have my road map, my strategy road map, a little bit where do we stand by end of May. Then I think very interesting for you at 10:00 around with Marc Ammann, our EVP, Innovation, Digitalization, Research and Development. Marc speaking about our road map and the sexy nail. And then I’m very happy to welcome Daniel Herren, Dr. Daniel Herren from the Schulthess Clinic in Zurich. He’s sitting there. And we thought we should invite the pope of CMC1 Prosthesis because you are not only placed, I don’t know how many you will discuss it. You will

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram WhatsApp

Related Articles

Upstart’s Breakout May Occur Sooner Than Expected – H2 2026 Macro Risks (NASDAQ:UPST)

Ametek: The Quiet Control Layer Behind The Next Industrial Investment Cycle (NYSE:AME)

Top 25 Dividend Stock Opportunities For September 2026

Cango Inc. (CANG) Q2 2026 Earnings Call Transcript

Betmakers Technology Group Ltd (TPBTF) Q4 2026 Earnings Call Transcript

SPHB ETF: High Beta Means Strong Upside Capture But Weak Risk-Adjusted Returns;, Hold

Shui On Land Limited 2026 Q2 – Results – Earnings Call Presentation (OTCMKTS:SOLLY) 2026-08-31

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia Transcript

Pzena Focused Credit Opportunities Q2 2026 Commentary

Editors Picks

Ametek: The Quiet Control Layer Behind The Next Industrial Investment Cycle (NYSE:AME)

1 September 2026

Top 25 Dividend Stock Opportunities For September 2026

1 September 2026

Cango Inc. (CANG) Q2 2026 Earnings Call Transcript

1 September 2026

Betmakers Technology Group Ltd (TPBTF) Q4 2026 Earnings Call Transcript

1 September 2026

Subscribe to News

Get the latest finance and business news and updates directly to your inbox.

Latest Posts

SPHB ETF: High Beta Means Strong Upside Capture But Weak Risk-Adjusted Returns;, Hold

1 September 2026

Shui On Land Limited 2026 Q2 – Results – Earnings Call Presentation (OTCMKTS:SOLLY) 2026-08-31

1 September 2026

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia Transcript

31 August 2026
Facebook X (Twitter) Pinterest WhatsApp TikTok Instagram
© 2026 The Business Times. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.